Cargando…

Safety of breast feeding during rituximab treatment in multiple sclerosis

BACKGROUND: There are limited data on the safety of breast feeding during rituximab therapy. Our objective is to determine exposure from breast feeding and biological effects of rituximab in breastfed infants. METHODS: In our case series of six mother–infant pairs, the nursing mothers with relapsing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rød, Brit Ellen, Torkildsen, Øivind, Myhr, Kjell-Morten, Bø, Lars, Wergeland, Stig
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Multiple Sclerosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763193/ https://www.ncbi.nlm.nih.gov/pubmed/35879056 http://dx.doi.org/10.1136/jnnp-2022-329545

Ejemplares similares

Association of adverse childhood experiences with the development of multiple sclerosis
por: Eid, Karine, et al.
Publicado: (2022)

Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations
por: König, Marton, et al.
Publicado: (2023)

Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study
por: Lie, Ingrid Anne, et al.
Publicado: (2022)

Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study
por: Lunde, Hanne Marie Bøe, et al.
Publicado: (2017)

Mortality and cause of death in multiple sclerosis in western Norway 1950–2021: a registry-based linkage study
por: Willumsen, Johannes Sverre, et al.
Publicado: (2022)

Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT
por: Kvistad, Silje Agnethe Stokke, et al.
Publicado: (2022)

Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study
por: Torgauten, Hilde Marie, et al.
Publicado: (2021)

A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway
por: Grytten, N, et al.
Publicado: (2016)

Delayed B cell repopulation after rituximab treatment in multiple sclerosis patients with expanded adaptive natural killer cells
por: Moreira, Antía, et al.
Publicado: (2022)

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
por: Patti, F, et al.
Publicado: (2016)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis
por: Hedström, Anna Karin, et al.
Publicado: (2021)

Influence of oral tobacco versus smoking on multiple sclerosis disease activity and progression
por: Wu, Jing, et al.
Publicado: (2023)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

The contribution of neuropathology to multiple sclerosis research
por: Lassmann, Hans
Publicado: (2022)

Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study
por: Smith, Kelsi A, et al.
Publicado: (2023)

Brain age as a surrogate marker for cognitive performance in multiple sclerosis
por: Denissen, Stijn, et al.
Publicado: (2022)

Imaging outcomes for trials of remyelination in multiple sclerosis
por: Mallik, Shahrukh, et al.
Publicado: (2014)

Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis
por: Manjaly, Zina-Mary, et al.
Publicado: (2019)

Decision making and framing effects in multiple sclerosis
por: Zamarian, Laura, et al.
Publicado: (2020)

Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis
por: Montalban, Xavier, et al.
Publicado: (2023)

Insufficient sleep during adolescence and risk of multiple sclerosis: results from a Swedish case-control study
por: Åkerstedt, Torbjörn, et al.
Publicado: (2023)

Multiple sclerosis and COVID‐19: How many are at risk?
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Stressful life events are associated with the risk of multiple sclerosis
por: Jiang, X., et al.
Publicado: (2020)

Impact of CYBA genotypes on severity and progression of multiple sclerosis
por: Törnell, Andreas, et al.
Publicado: (2022)

Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?
por: Cerqueira, João J, et al.
Publicado: (2018)

The grey matter correlates of impaired decision-making in multiple sclerosis
por: Muhlert, Nils, et al.
Publicado: (2015)

MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis
por: Matthews, Lucy, et al.
Publicado: (2015)

Structural network disruption markers explain disability in multiple sclerosis
por: Charalambous, Thalis, et al.
Publicado: (2019)

Diagnosis and treatment of progressive multiple sclerosis: A position paper
por: Pozzilli, Carlo, et al.
Publicado: (2022)

Association of serum neurofilament light with microglial activation in multiple sclerosis
por: Saraste, Maija, et al.
Publicado: (2023)

DRB1–environment interactions in multiple sclerosis etiology: results from two Swedish case–control studies
por: Hedström, Anna Karin, et al.
Publicado: (2021)

Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme
por: Palace, Jacqueline, et al.
Publicado: (2019)

Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions
por: Muhlert, Nils, et al.
Publicado: (2014)

Tobacco smoking and excess mortality in multiple sclerosis: a cohort study
por: Manouchehrinia, Ali, et al.
Publicado: (2014)

Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2016)

Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics
por: Nij Bijvank, Jenny, et al.
Publicado: (2022)

Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Confirmed disability progression as a marker of permanent disability in multiple sclerosis
por: Sharmin, Sifat, et al.
Publicado: (2022)

Smartphone‐derived keystroke dynamics are sensitive to relevant changes in multiple sclerosis
por: Lam, Ka‐Hoo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uori4samjih2mbu48suupobc6s